A Phase 1 Study of the Safety and Tolerability of CTX-10726

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Compass Therapeutics
Study ID
NCT07419841
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Endometrial Cancer
  • Gastroesophageal Cancer (GC)
  • Hepatocellular Carcinoma (HCC)
  • Renal Cell Carcinoma (RCC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CTX-10726 — DRUG
    Intravenous (IV) infusion (0.3-10.0mg/kg) every two weeks.

Study Details

This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escalation and Cohort 2 Dose Expansion.

Key Dates

First listed
Feb 19, 2026
Start date
May 28, 2026
Status verified
Feb 2026
Primary completion
Apr 1, 2028
Completion
Nov 1, 2028

Study Design

Enrollment
70 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Escalation Cohort 1
    Escalating doses of CTX-10726
  • Experimental: Dose Expansion Cohort 2
    Dose of CTX-10726 depending on Cohort 1 data

Primary Outcome Measure

Cohort 1: Evaluate the safety and tolerability of CTX-10726 by incidence of treatment-emergent adverse events (TEAEs) in escalating doses [ Time Frame: From first dose of CTX-10726 (Cycle 1 Day 1, Cycle = 2 weeks) until 30 days after the last dose of CTX-10726, average of 6 months) ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Dana Farber Cancer InstituteBostonMassachusetts02215
Haeseong Park, MD
[email protected]
617-632-4500
Haeseong Park, MD (PRINCIPAL_INVESTIGATOR)
Nebraska Cancer SpecialistsOmahaNebraska68130
Ashley Servais
[email protected]
402-955-2691
Ralph Hauke, MD (PRINCIPAL_INVESTIGATOR)
START New YorkLake SuccessNew York11042
Camilita Goberdhan
[email protected]
347-476-1959
Geraldine O'Sullivan Coyne, MD, PhD (PRINCIPAL_INVESTIGATOR)
Prisma Health Cancer InstituteGreenvilleSouth Carolina29605
Jeff Edenfield, MD
[email protected]
864-455-3600
Jeff Edenfield, MD (PRINCIPAL_INVESTIGATOR)
SCRI Oncology PartnersNashvilleTennessee37203
Meredith Pelster, MD
[email protected]
844-482-4812
Meredith Pelster, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By condition
Endometrial cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Dana Farber Cancer Institute· Boston, MANebraska Cancer Specialists· Omaha, NESTART New York· Lake Success, NYPrisma Health Cancer Institute· Greenville, SCSCRI Oncology Partners· Nashville, TN

Related Studies